Every Cancer, a Different Screening

Cancer screening today is organ-specific (mammography for breast, colonoscopy for colon, PSA for prostate), invasive, facility-dependent, and covers only a handful of cancer types. Of the 200+ cancer types, fewer than 10 have recommended screening tests, and most require clinical visits, specialist equipment, or blood draws. Emerging multi-cancer early detection (MCED) blood tests (like Grail's Galleri) can screen for multiple cancers from a single blood draw, but achieve only 17–44% sensitivity for Stage 1 cancers — missing the majority of early-stage disease. No technology exists that can reliably detect 30+ cancer types at Stage 1 from a self-administered home sample (urine or breath) without clinical infrastructure.

Cancer kills nearly 10 million people globally per year. Five-year survival for cancers detected at Stage 1 exceeds 90% for most types, but drops below 30% for Stage 4 detection. Over 40% of cancers are diagnosed at Stage 3 or 4, often because no screening test exists for that cancer type. If a simple, at-home test could screen for dozens of cancers at Stage 1, it would fundamentally shift cancer from a late-diagnosed disease to an early-detected one. The potential lives saved are in the millions annually.

Blood-based MCED tests (Grail Galleri, EXACT Sciences, Freenome) detect circulating tumor DNA (ctDNA) or methylation signatures, but Stage 1 tumors shed extremely low levels of DNA into the blood — often below detection limits. Galleri's 17% sensitivity for Stage 1 means it misses 5 out of 6 early-stage cancers. Protein biomarker panels (like CancerSEEK) face high false-positive rates because individual cancer biomarkers are not specific — inflammation, benign conditions, and other diseases produce the same proteins. These approaches also require venipuncture and laboratory processing, limiting access and scalability. Urine and breath-based cancer detection research exists but is limited to single cancer types with cancer-specific volatile organic compounds, and none has achieved clinical validation.

Synthetic biology offers a fundamentally different approach: rather than relying on the trace endogenous signals that tumors naturally shed, engineered biological sensors could be administered (orally or via inhalation) that actively seek out and amplify cancer-specific signals into easily detectable reporters in urine or breath. This requires: (1) programmable biosensors that can detect multiple cancer-specific molecular markers (not just one); (2) tunable reporter systems that produce distinct, quantifiable signals for different cancer types; (3) a self-administered delivery format and a home-compatible detection device (smartphone-assisted or handheld reader) that is accurate enough for clinical decision-making without laboratory infrastructure.

A student team could design and test a synthetic gene circuit in cell culture that produces a detectable fluorescent or enzymatic reporter in response to a cancer-associated microRNA panel. A more engineering-focused team could prototype a handheld reader device for detecting synthetic reporter molecules in urine samples, benchmarking sensitivity and specificity against known concentrations. Relevant disciplines: synthetic biology, bioengineering, diagnostics, electrical engineering, human-computer interaction (for the home test UX).